PHAR

Pharming Group

1 day
0.00%
5 days
0.00%
1 month
0.00%
3 months
0.00%
6 months
0.00%
Year to date
0.00%
1 year
0.00%
5 years
0.00%
10 years
0.00%
 

About: Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Employees: 404

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

39% more capital invested

Capital invested by funds: $369K [Q3] → $514K (+$145K) [Q4]

20% more funds holding

Funds holding: 5 [Q3] → 6 (+1) [Q4]

0% more ownership

Funds ownership: 0.01% [Q3] → 0.01% (+0%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$37
Avg. target
$38
High target
$39

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Joseph Pantginis
20% 1-year accuracy
82 / 412 met price target
$37
Buy
Reiterated
21 Mar 2025
Oppenheimer
Michael Carrier
20% 1-year accuracy
2 / 10 met price target
$39
Outperform
Maintained
14 Mar 2025

Financial journalist opinion

Based on 3 articles about PHAR published over the past 30 days

Neutral
GlobeNewsWire
4 days ago
Pharming Group to report first quarter 2025 financial results on May 8
Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025.
Pharming Group to report first quarter 2025 financial results on May 8
Neutral
GlobeNewsWire
5 days ago
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive final guidance recommending Joenja® (leniolisib) for reimbursement and use within the National Health Service (NHS) in England and Wales for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Neutral
GlobeNewsWire
3 weeks ago
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website.
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Neutral
GlobeNewsWire
1 month ago
Pharming Group to participate in April investor conferences
Leiden, the  Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences in the month of April:
Pharming Group to participate in April investor conferences
Neutral
Seeking Alpha
1 month ago
Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Fabrice Chouraqui - CEO Stephen Toor - CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Ben Jackson – Jefferies Alistair Campbell - RBC Capital Markets Joe Pantginis - H.C.
Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Leiden, the Netherlands, March 13, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2024.
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Neutral
GlobeNewsWire
1 month ago
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Neutral
GlobeNewsWire
2 months ago
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this press release and in the offer document published on the transaction website ( www.raredisease-offer.com ). Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this press release .
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Neutral
GlobeNewsWire
3 months ago
Pharming Group to convene Extraordinary General Meeting of Shareholders
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET. The Notice to Convene, Explanatory Notes, Voting information, meeting documents and Form of Proxy can be found on the Company's website under Investors/Shareholder Meetings.
Pharming Group to convene Extraordinary General Meeting of Shareholders
Neutral
GlobeNewsWire
3 months ago
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Charts implemented using Lightweight Charts™